Literature DB >> 19657309

Diagnosis and treatment of pancreatic vasoactive intestinal peptide endocrine tumors.

Shaowei Song1, Rui Shi, Baifeng Li, Yongfeng Liu.   

Abstract

OBJECTIVE: To discuss our experience in diagnosing and treating pancreatic vasoactive intestinal peptide-secreting tumors (VIPomas) by summarizing clinical information of 4 patients.
METHOD: Clinical manifestations, laboratory examination, imaging features, surgical findings, and pathological findings of 4 patients with VIPoma admitted in our hospital from 1991 to the present are discussed.
RESULTS: Watery diarrhea and hypokalemia were the main clinical manifestations. Hepatic metastasis occurred in 2 patients. The pancreatic body and tail were the main locations of lesions. Two tumors were shown in the pancreatic body and tail in 1 patient. Two patients with hepatic metastases received a combination therapy of octreotide, surgery, and chemotherapy, which resulted in symptom improvement and normalization of the serum potassium values. Distal pancreatic resection and second resection of hepatic metastatic lesions were performed in 1 patient. Resection of the pancreatic body and tail was done in 1 patient, and pancreatoduodenectomy was performed in another patient. Laparotomy was done in 1 patient because of invasion of the superior mesenteric vein and duodenum.
CONCLUSIONS: Typical symptoms play an important role in the diagnosis of VIPoma. Octreotide therapy has advanced the preoperative electrolyte management, and the combination of octreotide, chemotherapy, and surgery may be helpful in metastatic disease.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19657309     DOI: 10.1097/MPA.0b013e3181b2bc7c

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  9 in total

Review 1.  Emergency therapy for liver metastases from advanced VIPoma: surgery or transarterial chemoembolization?

Authors:  Johann Dréanic; Céline Lepère; Mostafa El Hajjam; Hervé Gouya; Philippe Rougier; Romain Coriat
Journal:  Ther Adv Med Oncol       Date:  2016-07-05       Impact factor: 8.168

2.  Pancreatic neuroendocrine tumors: approach to treatment with focus on sunitinib.

Authors:  Aaron I Vinik; Eric Raymond
Journal:  Therap Adv Gastroenterol       Date:  2013-09       Impact factor: 4.409

3.  Multiple-phase spiral CT findings of pancreatic vasoactive intestinal peptide-secreting tumor: A case report.

Authors:  Ying Chen; Dan Shi; Fei Dong; Shu-Gao Han; Zi-Hua Qian; L I Yang; Ying Wang; Ri-Sheng Yu; Qing-Hai Li; Yan-Biao Fu
Journal:  Oncol Lett       Date:  2015-08-17       Impact factor: 2.967

Review 4.  Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumours, current aspects and new perspectives.

Authors:  Marialuisa Appetecchia; Roberto Baldelli
Journal:  J Exp Clin Cancer Res       Date:  2010-03-02

Review 5.  Systemic therapy for advanced pancreatic neuroendocrine tumors.

Authors:  Matthew H Kulke
Journal:  Semin Oncol       Date:  2013-02       Impact factor: 4.929

Review 6.  Functional, Diagnostic and Therapeutic Aspects of Gastrointestinal Hormones.

Authors:  Monjur Ahmed; Sarah Ahmed
Journal:  Gastroenterology Res       Date:  2019-10-04

7.  Vasoactive Intestinal Peptide Tumor as the Cause of Persistent Diarrhea: A Diagnostic Challenge.

Authors:  Sara Lopes; Marta Alves; Pedro Rodrigues
Journal:  Cureus       Date:  2022-09-13

Review 8.  Role of Somatostatin Receptor in Pancreatic Neuroendocrine Tumor Development, Diagnosis, and Therapy.

Authors:  Yuheng Hu; Zeng Ye; Fei Wang; Yi Qin; Xiaowu Xu; Xianjun Yu; Shunrong Ji
Journal:  Front Endocrinol (Lausanne)       Date:  2021-05-19       Impact factor: 5.555

Review 9.  Somatostatin analogs therapy in gastroenteropancreatic neuroendocrine tumors: current aspects and new perspectives.

Authors:  Roberto Baldelli; A Barnabei; L Rizza; A M Isidori; F Rota; P Di Giacinto; A Paoloni; F Torino; S M Corsello; A Lenzi; M Appetecchia
Journal:  Front Endocrinol (Lausanne)       Date:  2014-02-07       Impact factor: 5.555

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.